Kumar Nagi B, Dickinson Shohreh I, Schell Michael J, Manley Brandon J, Poch Michael A, Pow-Sang Julio
H. Lee Moffitt Cancer Center & Research Institute, Inc., Cancer Epidemiology, MRC/CANCONT, Tampa, FL 33612-9497, USA.
H. Lee Moffitt Cancer Center & Research Institute, Inc., Pathology Anatomic MMG, WCB-GU PROG, Tampa, FL 33612-9497, USA.
Oncotarget. 2018 Dec 28;9(102):37798-37806. doi: 10.18632/oncotarget.26519.
Active surveillance (AS) has evolved as a management strategy for men with low grade prostate cancer (PCa). However, these patients report anxiety, doubts about the possible progression of the disease as well as higher decisional conflict regarding selection of active surveillance, and have been reported to ultimately opt for treatment without any major change in tumor characteristics. Currently, there is a paucity of research that systematically examines alternate strategies for this target population.
We conducted a review the evidence from epidemiological, , preclinical and early phase trials that have evaluated green tea catechins (GTC) for secondary chemoprevention of prostate cancer, focused on men opting for active surveillanceof low grade PCa.
Results of our review of the , preclinical and phase I-II trials, demonstrates that green tea catechins (GTC) can modulate several relevant intermediate biological intermediate endpoint biomarkers implicated in prostate carcinogenesis as well as clinical progression of PCa, without major side effects.
Although clinical trials using GTC have been evaluated in early phase trials in men diagnosed with High-Grade Prostatic Intraepithelial Neoplasia, Atypical Small Acinar Proliferation and in men with localized disease before prostatectomy, the effect of GTC on biological and clinical biomarkers implicated in prostate cancer progression have not been evaluated in this patient population.
Results of these studies promise to provide a strategy for secondary chemoprevention, reduce morbidities due to overtreatment and improve quality of life in men diagnosed with low-grade PCa.
主动监测（AS）已发展成为低级别前列腺癌（PCa）男性患者的一种管理策略。然而，这些患者报告有焦虑情绪，对疾病可能进展存在疑虑，并且在选择主动监测方面存在更高的决策冲突，据报道最终会选择治疗，而肿瘤特征并无任何重大变化。目前，缺乏系统研究针对这一目标人群的替代策略。
我们对流行病学、临床前和早期试验的证据进行了综述，这些试验评估了绿茶儿茶素（GTC）用于前列腺癌的二级化学预防，重点关注选择对低级别PCa进行主动监测的男性。
我们对临床前和I-II期试验的综述结果表明，绿茶儿茶素（GTC）可以调节前列腺癌发生以及PCa临床进展中涉及的几个相关中间生物中间终点生物标志物，且无重大副作用。
尽管使用GTC的临床试验已在诊断为高级别前列腺上皮内瘤变、非典型小腺泡增生的男性以及前列腺切除术前患有局限性疾病的男性的早期试验中进行了评估，但GTC对前列腺癌进展中涉及的生物和临床生物标志物的影响尚未在该患者群体中进行评估。
这些研究结果有望提供一种二级化学预防策略，减少过度治疗导致的发病率，并改善诊断为低级别PCa的男性的生活质量。
